-
Deadly strikes across Mideast as Iran vows revenge on slain security chief
-
Japan, S. Korea petrochemical industry slows output on Iran war
-
Chinese tourists ditch Japan for third month running
-
Record setters Duplantis, Hodgkinson headline Torun world indoors
-
Chinese visitors to Japan plunge 45.2% in February
-
BTS light stick prices surge ahead of comeback concert
-
'Special human' Slipper to break Super Rugby appearance record
-
Brussels to unveil 'EU Inc' pan-European company status
-
Iran to hold funeral for slain security chief as it vows vengeance
-
Greenland's teenage boxers throwing punches to survive
-
TotalEnergies faces ruling in Belgian farmer climate case
-
Brazil starts to restrict minors' access to social media
-
Trespasser caught in viral hippo Moo Deng's Thai zoo pen
-
Gilgeous-Alexander scores 40 as Thunder clinch playoff berth
-
Venezuela stun United States to win World Baseball Classic
-
Stocks extend gains and oil dips as US, Israel, Iran continue strikes
-
Iran missile fire kills two in central Israel: medics
-
Britain, Rwanda in £100m court clash over migrant deal
-
'We will wait for each one': Ukrainians greet POWs with tears and cheers
-
UN watchdog says projectile struck Iran nuclear power plant
-
Trump faces impasse over Iran war
-
US Fed expected to hold rates steady as Iran war's shockwaves ripple
-
Former Australian Test wicketkeeper Haddin to coach NSW
-
China coach says team on right track despite Asian Cup heartache
-
Oscars audience drops, viewing figures show
-
Resilient Australia 'need to be better' in Women's Asian Cup final
-
Gio Reyna picked for US squad as Pochettino says World Cup roster still 'open'
-
Colombia, Ecuador leaders clash over bomb dropped near border
-
A.D. Banker Launches Investment Adviser Representative Continuing Education, Making Compliance Simple
-
Botox in Bellevue, Washington
-
Augusta Precious Metals Reviews Highlight Growing Demand for Top Gold IRA Companies (2026 Industry Insights)
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 18
-
PSG, Real Madrid and Arsenal march into Champions League last eight
-
'Incomplete' Man City not what they once were, says Guardiola
-
US judge orders Trump admin to bring VOA employees back to work
-
White House pressure on Cuba mounts as island fights power cut
-
Arteta hails 'magical' Eze after Arsenal star sinks Leverkusen
-
Senegal stripped of AFCON title, Morocco declared champions
-
Nvidia says restarting production of China-bound chips
-
Panic as Israel army urges residents to evacuate south Lebanon's Tyre area
-
Real Madrid 'change' under Champions League spotlight: Vinicius
-
Real Madrid dump Man City out of Champions League once more
-
Clinical PSG bury Chelsea to reach Champions League quarter-finals
-
Eze rocket fires Arsenal into Champions League quarters
-
US airlines still see strong demand as jet fuel worries loom
-
Milei blasts Iran on anniversary of attack on Israeli embassy
-
USS Gerald R. Ford: the world's biggest aircraft carrier
-
US, European stocks rise despite latest jump in oil prices
-
Sporting Lisbon thrash Bodo/Glimt to reach Champions League quarters
-
Irish PM pushes Trump on Iran -- politely
Biden calls for lower prices of Ozempic, similar drugs
US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."
In an article written with Senator Bernie Sanders, Biden said US patients pay several times more than in Canada, Germany and Denmark for Nordisk's diabetes drugs Ozempic and Wegovy, which can also be used for weight loss.
One-month supply of Ozempic in the United States last year was $936, compared to $169 in Canada and $103 in Germany, according to one study.
Eli Lilly was also charging "unconscionably high prices" for Mounjaro, a drug similar to Ozempic.
"Why should people in Burlington, Vermont, pay so much more than people in Copenhagen or Berlin for the same drug?" wrote Biden and Sanders, who chairs the Senate healthcare committee.
Such "price gouging" makes the drugs unaffordable to millions of Americans, they said.
"If the prices of these drugs are not substantially reduced, they have the potential to bankrupt the American health care system," Biden and Sanders wrote. "We will not allow that to happen."
Nordisk and Lilly did not immediately respond to an AFP request for comment.
High prices for prescription drugs have been a long-standing problem for American patients, and Democrat Biden has focused on lowering healthcare costs as part of his reelection campaign in November.
The piece in USA Today comes days after Biden's weak performance during a televised presidential debate with Republican Donald Trump sparked sharp concern among Democrats.
M.Fischer--AMWN